Lataa...
Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
In the therapeutic scenario of disease-modifying therapies for relapsing–remitting multiple sclerosis, the introduction of oral agents, starting in 2010 with fingolimod, has been a huge step forward in therapeutic options due to the easier administration route. Three oral drugs fingolimod, terifluno...
Tallennettuna:
| Julkaisussa: | Drug Des Devel Ther |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5546180/ https://ncbi.nlm.nih.gov/pubmed/28814828 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S137572 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|